Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help
This article was originally published in The Pink Sheet Daily
Executive Summary
Tysabri’s REMS could prove to be a model for drugs with serious safety signals.
You may also be interested in...
Safety Remains Front-Line Concern For Oral MS Drugs
Two drugs in a race to become the first oral treatment for relapsing forms of multiple sclerosis have high safety hurdles to overcome, obstacles that may knock them both out of the running as first-line treatments.
Safety Remains Front Line Concern For Oral MS Drugs
Merck Serono’s cladribine Tablets and Novartis’ fingolimod could be relegated to second line or later treatments.
Safety Remains Front-Line Concern For Oral MS Drugs
Two drugs in a race to become the first oral treatment for relapsing forms of multiple sclerosis have high safety hurdles to overcome, obstacles that may knock them both out of the running as first-line treatments.